Azole derivatives in the form of lipase and phospholipase inhibitors

1. A compound of the formula I

in which:

A is S or O;

W is —(C═O)—, —(S═O)— and —(SO 2 )—;

X is identically or differently ═C(—R)—;

Y is —O— or —NR1-;

R is hydrogen, halogen, (C 1 -C 6 )-alkyl, (C 1 -C 3 )-alkyloxy-(C 1 -C 3 )-alkylene, hydroxy, (C 1 -C 6 )-alkylmercapto, amino, (C 1 -C 6 )-alkylamino, di-(C 2 -C 12 )-alkylamino, mono-(C 1 -C 6 )-alkylaminocarbonyl, di-(C 2 -C 8 )-alkylamino-carbonyl, COOR4, trifluoromethyl, (C 1 -C 6 )-alkylsulfonyl, (C 1 -C 6 )-alkylsulfinyl, aminosulfonyl, nitro, pentafluorosulfanyl, (C 6 -C 10 )-aryl, CO—NR2R3, O—CO—NR2R3, O—CO—(C 1 -C 6 )-alkylene —CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—NR2R3 or unsubstituted or mono- or poly-F-substituted (C 1 -C 6 )-alkyloxy;

R1 is hydrogen, (C 1 -C 6 )-alkyl, benzyl;

NR2R3 is piperidine which comprises the atomic member CHR5 in position 4;

R4 is hydrogen, (C 1 -C 6 )-alkyl, benzyl;

R5 is (C 1 -C 6 )-alkyl, halogen, trifluoromethyl, cyclopropyl, cyclopropylene;

The tautomeric forms of the compound and the physiologically tolerated salts thereof.

2. The compound of formula I as claimed in claim 1 , wherein X in position 4 and 5 is ═C(—R)— with R=hydrogen, and in position 6 R is not hydrogen.

3. A medicament comprising one or more compounds of formula I as claimed in claim 1 .

4. A medicament as claimed in claim 3 , which further comprises at least one additional active ingredient selected from antidiabetics, hypoglycemic active ingredients, HMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients acting on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin antagonists, H3 agonists, TNF agonists, CRF antagonists, CRF BP antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators, TR-β agonists and amphetamines.

5. A medicament comprising one or more of the compounds of formula I as claimed in claim 1 in admixture with a pharmaceutically suitable carrier in a form suitable for administration.

6. A process for preparing a compound of formula I as claimed in claim 1 which comprises either (1) acylating an azole of formula II with a carbamoyl chloride of formula III;

or

(2) reacting said azole of formula II in two stages, first with phosgene or an equivalent thereof, such as trichloromethyl chlorocarbonate, ditrichloromethyl carbonate or 4-nitrophenyl chloroformate, and thereafter, in a second step, reacting the resulting product with an amine of formula IV, as summarized in the following scheme, in which the substituents are as defined in claim 1

7. A process for preparing a compound of general formula I wherein R3 is hydrogen (formula Ia) as claimed in claim 1 , which comprises reacting an azole of formula II with an isocyanate of formula V, O═C═N—R2, as summarized in the following reaction scheme, in which the substituents are as defined in claim 1